Pneumococcal Vaccine Candidate Targeting 25 Serotypes Advances
(MedPage Today) -- WASHINGTON -- A pneumococcal conjugate vaccine (PCV) covering 25 serotypes was safe and generated immune responses among infants that were comparable to the current 20-valent vaccine (Prevnar 20), a phase II trial showed....
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.